| Ident. | Authors (with country if any) | Title |
|---|
| 000665 (2017) |
Christophe Hézode ; Massimo Colombo ; Marc Bourlière ; Ulrich Spengler ; Ziv Ben-Ari ; Simone I. Strasser ; William M. Lee ; Leslie Morgan ; Jingjun Qiu ; Peggy Hwang ; Michael Robertson ; Bach-Yen Nguyen ; Eliav Barr ; Janice Wahl ; Barbara Haber ; Robert Chase ; Rohit Talwani ; Vito Di Marco | Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. |
| 000A38 (2017) |
Marc Bourlière ; Stuart C. Gordon ; Steven L. Flamm ; Curtis L. Cooper ; Alnoor Ramji ; Myron Tong ; Natarajan Ravendhran ; John M. Vierling ; Tram T. Tran ; Stephen Pianko ; Meena B. Bansal ; Victor De Lédinghen ; Robert H. Hyland ; Luisa M. Stamm ; Hadas Dvory-Sobol ; Evguenia Svarovskaia ; Jie Zhang ; K C Huang ; G Mani Subramanian ; Diana M. Brainard ; John G. Mchutchison ; Elizabeth C. Verna ; Peter Buggisch ; Charles S. Landis ; Ziad H. Younes ; Michael P. Curry ; Simone I. Strasser ; Eugene R. Schiff ; K Rajender Reddy ; Michael P. Manns ; Kris V. Kowdley ; Stefan Zeuzem | Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. |
| 001019 (2017) |
Mark S. Sulkowski ; Walford J. Fessel ; Adriano Lazzarin ; Juan Berenguer ; Natalia Zakharova ; Hugo Cheinquer ; Pierre Côté ; Douglas Dieterich ; Adrian Gadano ; Gail Matthews ; Jean-Michel Molina ; Christophe Moreno ; Juan Antonio Pineda ; Federico Pulido ; Antonio Rivero ; Jurgen Rockstroh ; Dennis Hernandez ; Fiona Mcphee ; Timothy Eley ; Zhaohui Liu ; Patricia Mendez ; Eric Hughes ; Stephanie Noviello ; Peter Ackerman | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. |
| 001456 (2016) |
E. Keoshkerian ; M. Hunter ; B. Cameron ; N. Nguyen ; P. Sugden ; R. Bull ; A. Zekry ; L. Maher ; N. Seddiki ; J. Zaunders ; A. Kelleher ; A R Lloyd | Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection. |
| 001457 (2016) |
Jason Grebely ; Stefan Mauss ; Ashley Brown ; Jean-Pierre Bronowicki ; Massimo Puoti ; David Wyles ; Macky Natha ; Yanni Zhu ; Junming Yang ; Bruce Kreter ; Diana M. Brainard ; Chohee Yun ; Val Carr ; Gregory J. Dore | Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. |
| 001A15 (2016) |
Andrew Richard Armstrong ; Susan Elizabeth Herrmann ; Olivier Chassany ; Christophe Lalanne ; Mariliza Henrique Da Silva ; Eliana Galano ; Patrizia M. Carrieri ; Vincent Estellon ; Philippe Sogni ; Martin Duracinsky | The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus. |
| 001E20 (2016) |
Michael Manns ; Didier Samuel ; Edward J. Gane ; David Mutimer ; Geoff Mccaughan ; Maria Buti ; Martín Prieto ; José Luis Calleja ; Markus Peck-Radosavljevic ; Beat Müllhaupt ; Kosh Agarwal ; Peter Angus ; Eric M. Yoshida ; Massimo Colombo ; Mario Rizzetto ; Hadas Dvory-Sobol ; Jill Denning ; Sarah Arterburn ; Phillip S. Pang ; Diana Brainard ; John G. Mchutchison ; Jean-François Dufour ; Hans Van Vlierberghe ; Bart Van Hoek ; Xavier Forns | Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. |
| 001E90 (2016) |
Vincent Leroy ; Peter Angus ; Jean-Pierre Bronowicki ; Gregory J. Dore ; Christophe Hezode ; Stephen Pianko ; Stanislas Pol ; Katherine Stuart ; Edmund Tse ; Fiona Mcphee ; Rafia Bhore ; Maria Jesus Jimenez-Exposito ; Alexander J. Thompson | Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). |
| 002176 (2016) |
Tarik Asselah ; Alex J. Thompson ; Robert Flisiak ; Manuel Romero-Gomez ; Diethelm Messinger ; Georgios Bakalos ; Mitchell L. Shiffman | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. |
| 002592 (2015) |
Tarik Asselah ; Stefan Zeuzem ; Vicente Soriano ; Jean-Pierre Bronowicki ; Ansgar W. Lohse ; Beat Müllhaupt ; Marcus Schuchmann ; Marc Bourlière ; Maria Buti ; Stuart K. Roberts ; Edward J. Gane ; Jerry O. Stern ; Florian Voss ; Patrick Baum ; John-Paul Gallivan ; Wulf O. Böcher ; Federico J. Mensa | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. |
| 002603 (2015) |
Graham R. Foster ; Nezam Afdhal ; Stuart K. Roberts ; Norbert Br U ; Edward J. Gane ; Stephen Pianko ; Eric Lawitz ; Alex Thompson ; Mitchell L. Shiffman ; Curtis Cooper ; William J. Towner ; Brian Conway ; Peter Ruane ; Marc Bourlière ; Tarik Asselah ; Thomas Berg ; Stefan Zeuzem ; William Rosenberg ; Kosh Agarwal ; Catherine A M. Stedman ; Hongmei Mo ; Hadas Dvory-Sobol ; Lingling Han ; Jing Wang ; John Mcnally ; Anu Osinusi ; Diana M. Brainard ; John G. Mchutchison ; Francesco Mazzotta ; Tram T. Tran ; Stuart C. Gordon ; Keyur Patel ; Nancy Reau ; Alessandra Mangia ; Mark Sulkowski | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. |
| 002917 (2015) |
Che C. Colpitts ; Joachim Lupberger ; Christian Doerig ; Thomas F. Baumert | Host cell kinases and the hepatitis C virus life cycle. |
| 002921 (2015) |
S. Rüeger ; P-Y Bochud ; J-F Dufour ; B. Müllhaupt ; D. Semela ; M H Heim ; D. Moradpour ; A. Cerny ; R. Malinverni ; D R Booth ; V. Suppiah ; J. George ; L. Argiro ; P. Halfon ; M. Bourlière ; A H Talal ; I M Jacobson ; E. Patin ; B. Nalpas ; T. Poynard ; S. Pol ; L. Abel ; Z. Kutalik ; F. Negro | Impact of common risk factors of fibrosis progression in chronic hepatitis C. |
| 002932 (2015) |
Antonia Lepida ; Massimo Colombo ; Inmaculada Fernandez ; Djamal Abdurakhmanov ; Paulo Abrao Ferreira ; Simone I. Strasser ; Petr Urbanek ; Alessandra Mangia ; José L. Calleja ; Wafae Iraqi ; Ralph Demasi ; Isabelle Lonjon-Domanec ; Christophe Moreno ; Heiner Wedemeyer | Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. |
| 002A81 (2015) |
Jürgen K. Rockstroh ; Mark Nelson ; Christine Katlama ; Jay Lalezari ; Josep Mallolas ; Mark Bloch ; Gail V. Matthews ; Michael S. Saag ; Philippe J. Zamor ; Chloe Orkin ; Jacqueline Gress ; Stephanie Klopfer ; Melissa Shaughnessy ; Janice Wahl ; Bach-Yen T. Nguyen ; Eliav Barr ; Heather L. Platt ; Michael N. Robertson ; Mark Sulkowski | Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. |
| 002D63 (2015) |
Andrew J. Muir ; Fred Poordad ; Jacob Lalezari ; Gregory Everson ; Gregory J. Dore ; Robert Herring ; Aasim Sheikh ; Paul Kwo ; Christophe Hézode ; Paul J. Pockros ; Albert Tran ; Joseph Yozviak ; Nancy Reau ; Alnoor Ramji ; Katherine Stuart ; Alexander J. Thompson ; John Vierling ; Bradley Freilich ; James Cooper ; Wayne Ghesquiere ; Rong Yang ; Fiona Mcphee ; Eric A. Hughes ; E Scott Swenson ; Philip D. Yin | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. |
| 002D97 (2015) |
Fred Poordad ; William Sievert ; Lindsay Mollison ; Michael Bennett ; Edmund Tse ; Norbert Br U ; James Levin ; Thomas Sepe ; Samuel S. Lee ; Peter Angus ; Brian Conway ; Stanislas Pol ; Nathalie Boyer ; Jean-Pierre Bronowicki ; Ira Jacobson ; Andrew J. Muir ; K Rajender Reddy ; Edward Tam ; Grisell Ortiz-Lasanta ; Victor De Lédinghen ; Mark Sulkowski ; Navdeep Boparai ; Fiona Mcphee ; Eric Hughes ; E Scott Swenson ; Philip D. Yin | Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. |
| 002F36 (2015) |
Jean-Michel Molina ; Chloe Orkin ; David M. Iser ; Francisco-Xavier Zamora ; Mark Nelson ; Christoph Stephan ; Benedetta Massetto ; Anuj Gaggar ; Liyun Ni ; Evguenia Svarovskaia ; Diana Brainard ; G Mani Subramanian ; John G. Mchutchison ; Massimo Puoti ; Jürgen K. Rockstroh | Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. |
| 002F88 (2015) |
Eric Lawitz ; Edward Gane ; Brian Pearlman ; Edward Tam ; Wayne Ghesquiere ; Dominique Guyader ; Laurent Alric ; Jean-Pierre Bronowicki ; Laura Lester ; William Sievert ; Reem Ghalib ; Luis Balart ; Fredrik Sund ; Martin Lagging ; Frank Dutko ; Melissa Shaughnessy ; Peggy Hwang ; Anita Y M. Howe ; Janice Wahl ; Michael Robertson ; Eliav Barr ; Barbara Haber | Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. |
| 003078 (2015) |
Gregory J. Dore ; Eric Lawitz ; Christophe Hézode ; Stephen D. Shafran ; Alnoor Ramji ; Harvey A. Tatum ; Gloria Taliani ; Albert Tran ; Maurizia R. Brunetto ; Serena Zaltron ; Simone I. Strasser ; Nina Weis ; Wayne Ghesquiere ; Samuel S. Lee ; Dominique Larrey ; Stanislas Pol ; Hugh Harley ; Jacob George ; Scott K. Fung ; Victor De Lédinghen ; Peggy Hagens ; Fiona Mcphee ; Dennis Hernandez ; David Cohen ; Elizabeth Cooney ; Stephanie Noviello ; Eric A. Hughes | Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. |
| 003121 (2015) |
K Rajender Reddy ; Stefan Zeuzem ; Fabien Zoulim ; Ola Weiland ; Andrzej Horban ; Carol Stanciu ; Federico Guillermo Villamil ; Pietro Andreone ; Jacob George ; Elisabeth Dammers ; Min Fu ; Darryl Kurland ; Oliver Lenz ; Sivi Ouwerkerk-Mahadevan ; Thierry Verbinnen ; Jane Scott ; Wolfgang Jessner | Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. |
